Last reviewed · How we verify
Drug: AC-170 0.24%
AC-170 is a topical ophthalmic agent that reduces intraocular pressure, likely through enhanced aqueous humor outflow or reduced production.
AC-170 is a topical ophthalmic agent that reduces intraocular pressure, likely through enhanced aqueous humor outflow or reduced production. Used for Glaucoma, Ocular hypertension.
At a glance
| Generic name | Drug: AC-170 0.24% |
|---|---|
| Also known as | 1 drop in each eye 2 times daily for up to 6 weeks |
| Sponsor | Aciex Therapeutics, Inc. |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
AC-170 is being developed as a novel therapeutic for glaucoma and ocular hypertension. The exact molecular mechanism is not publicly disclosed in detail, but the 0.24% concentration formulation suggests a topical eye drop designed to modulate intraocular pressure through one or more pathways affecting aqueous humor dynamics.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
Key clinical trials
- A Comparison of the Safety and Comfort of AC-170 (PHASE1)
- A Multi-Center Study Evaluating the Safety of AC-170 0.24% (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug: AC-170 0.24% CI brief — competitive landscape report
- Drug: AC-170 0.24% updates RSS · CI watch RSS
- Aciex Therapeutics, Inc. portfolio CI